Literature DB >> 15956985

Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.

Kimmo Ingman1, Nora Hagelberg, Sargo Aalto, Kjell Någren, Auni Juhakoski, Sakari Karhuvaara, Antero Kallio, Vesa Oikonen, Jarmo Hietala, Harry Scheinin.   

Abstract

The opioid antagonist nalmefene offers an alternative to traditional pharmacological treatments for alcoholism. The present study was designed to investigate the relationship between nalmefene plasma concentration and central mu-opioid receptor occupancy after a clinically effective dose (20 mg, orally). Pharmacokinetics and mu-opioid receptor occupancy of nalmefene after single and repeated dosing over 7 days was studied in 12 healthy subjects. Serial blood samples were obtained after both dosings, and pharmacokinetic parameters for nalmefene and main metabolites were determined. Central mu-opioid receptor occupancy of nalmefene was measured with positron emission tomography (PET) and [(11)C]carfentanil at four time points (3, 26, 50, 74 h) after both dosings. Nalmefene was rapidly absorbed in all subjects. The mean t(1/2) of nalmefene was 13.4 h after single and repeated dosing. The accumulation of nalmefene and its main metabolites in plasma during the repeated dosing period was as expected for a drug with linear pharmacokinetics, and steady-state was reached for all analytes. Both nalmefene dosings resulted in a very high occupancy at mu-opioid receptors (87-100%), and the decline in the occupancy was similar after both dosings but clearly slower than the decline in the plasma concentration of nalmefene or metabolites. High nalmefene occupancy (83-100%) persisted at 26 h after the dosings. The prolonged mu-opioid receptor occupancy by nalmefene indicates slow dissociation of the drug from mu-opioid receptors. These results support the rational of administering nalmefene when needed before alcohol drinking, and they additionally suggest that a high mu-opioid receptor occupancy can be maintained when nalmefene is taken once daily.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956985     DOI: 10.1038/sj.npp.1300790

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  19 in total

1.  Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.

Authors:  Lars-Erik Broksoe Kyhl; Shen Li; Kirstine Ullitz Faerch; Birgitte Soegaard; Frank Larsen; Johan Areberg
Journal:  Br J Clin Pharmacol       Date:  2016-01-27       Impact factor: 4.335

Review 2.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

3.  Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.

Authors:  Pablo Barrio; Lluisa Ortega; Josep Guardia; Carlos Roncero; Lara Yuguero; Antoni Gual
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 4.  [Nalmefene: a novel pharmacotherapeutic option for alcoholism].

Authors:  M Soyka
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

5.  Severe opioid withdrawal syndrome after a single dose of nalmefene.

Authors:  Nadine Donnerstag; Tobias Schneider; Adrian Lüthi; Anne Taegtmeyer; Alexandra Raetz Bravo; Annekathrin Mehlig
Journal:  Eur J Clin Pharmacol       Date:  2015-06-07       Impact factor: 2.953

6.  Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.

Authors:  Javier Calleja-Conde; Victor Echeverry-Alzate; Elena Giné; Kora-Mareen Bühler; Roser Nadal; Rafael Maldonado; Fernando Rodríguez de Fonseca; Antoni Gual; Jose Antonio López-Moreno
Journal:  Br J Pharmacol       Date:  2016-07-18       Impact factor: 8.739

7.  Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Authors:  Jørgen Matz; Claus Graff; Petri J Vainio; Antero Kallio; Astrid Maria Højer; Johannes J Struijk; Jørgen K Kanters; Mads P Andersen; Egon Toft
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

Review 8.  [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].

Authors:  M Gahr; M A Kölle; C Schönfeldt-Lecuona
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

9.  Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.

Authors:  Albert J Arias; Stephen Armeli; Joel Gelernter; Jonathan Covault; Antero Kallio; Sakari Karhuvaara; Tiina Koivisto; Rauno Mäkelä; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

10.  Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects.

Authors:  Jussi Hirvonen; Sargo Aalto; Nora Hagelberg; Anu Maksimow; Kimmo Ingman; Vesa Oikonen; Jussi Virkkala; Kjell Någren; Harry Scheinin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.